Zimmer Biomet Holdings Inc (NYSE:ZBH) – Research analysts at Piper Jaffray Companies raised their Q4 2019 earnings per share (EPS) estimates for Zimmer Biomet in a report issued on Tuesday, November 5th. Piper Jaffray Companies analyst M. O’brien now forecasts that the medical equipment provider will post earnings of $2.26 per share for the quarter, up from their prior estimate of $2.22. Piper Jaffray Companies also issued estimates for Zimmer Biomet’s Q1 2020 earnings at $2.03 EPS, Q2 2020 earnings at $2.07 EPS, Q4 2020 earnings at $2.29 EPS, FY2020 earnings at $8.29 EPS, Q1 2021 earnings at $2.18 EPS, Q2 2021 earnings at $2.22 EPS, Q3 2021 earnings at $2.05 EPS and FY2021 earnings at $8.91 EPS.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.02. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a positive return on equity of 13.89% and a negative net margin of 1.14%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.63 earnings per share.
Other equities research analysts also recently issued reports about the company. Royal Bank of Canada upped their target price on Zimmer Biomet from $145.00 to $155.00 and gave the stock an “outperform” rating in a research report on Wednesday. Citigroup upped their target price on Zimmer Biomet from $146.00 to $158.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Credit Suisse Group upped their target price on Zimmer Biomet from $101.00 to $120.00 and gave the stock an “underperform” rating in a research report on Monday, July 29th. TheStreet upgraded Zimmer Biomet from a “c+” rating to a “b” rating in a research report on Tuesday. Finally, BTIG Research upgraded Zimmer Biomet from a “neutral” rating to a “buy” rating and set a $158.00 price objective for the company in a research report on Monday, October 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $147.95.
ZBH traded up $2.07 during trading on Friday, reaching $144.00. The stock had a trading volume of 997,802 shares, compared to its average volume of 1,183,991. The firm has a market capitalization of $28.81 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 2.66 and a beta of 1.14. The company has a quick ratio of 0.56, a current ratio of 1.19 and a debt-to-equity ratio of 0.58. Zimmer Biomet has a 1-year low of $96.99 and a 1-year high of $144.96. The stock has a 50 day moving average of $136.99 and a two-hundred day moving average of $128.52.
The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date was Friday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.
In other news, insider Didier Deltort sold 360 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $139.25, for a total value of $50,130.00. Following the transaction, the insider now directly owns 1,194 shares of the company’s stock, valued at $166,264.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Chad F. Phipps sold 32,800 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $140.00, for a total transaction of $4,592,000.00. The disclosure for this sale can be found here. Insiders sold 40,244 shares of company stock worth $5,621,885 over the last ninety days. 0.72% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of ZBH. Personal Wealth Partners acquired a new position in Zimmer Biomet during the second quarter worth $26,000. TRUE Private Wealth Advisors acquired a new position in Zimmer Biomet during the second quarter worth $26,000. Allworth Financial LP increased its position in Zimmer Biomet by 65.0% during the third quarter. Allworth Financial LP now owns 203 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 80 shares during the last quarter. Coastal Investment Advisors Inc. increased its position in Zimmer Biomet by 271.0% during the second quarter. Coastal Investment Advisors Inc. now owns 256 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 187 shares during the last quarter. Finally, Private Ocean LLC increased its position in Zimmer Biomet by 34.8% during the second quarter. Private Ocean LLC now owns 310 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 80 shares during the last quarter. 87.72% of the stock is currently owned by hedge funds and other institutional investors.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
See Also: Initial Coin Offering (ICO)
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.